TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, Nina Raulf et al.|Cell Reports Medicine|2025Cited by 12
Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockadeRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cancer Research|2023Cited by 1